These results suggest that the inhibition of PD-1/PD-L1 binding in the tumor microenvironment may have anti-tumor effects in cats, and provide the fundamental tools for the establishment of immune checkpoint molecular inhibition therapy in cats as well as in humans and dogs. This evidence concerns the gene PDCD1 and neoplasm.